← Oncology Approval Tracker

FDA DECISION ·

Tafinlar + Mekinist

dabrafenib + trametinib · Novartis

FDA approvalNew or expanded indicationGlioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For children aged one year or older with BRAF V600E-mutant low-grade glioma requiring systemic treatment. FDA also approved oral formulations for patients unable to swallow pills.

LAMPGEN ANALYSIS

Why it matters

The combination offered biomarker-directed treatment for pediatric low-grade glioma with age-appropriate administration options.

What research teams should watch

Confirm the BRAF variant, systemic-treatment need and the child's ability to use the prescribed oral formulation.

PRIMARY RECORDS

Sources